← All Veracyte, INC filings

Veracyte, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
VCYT
Veracyte, INC
10-K: Veracyte Reports Strong 2025 Growth, Expands Cancer Diagnostics
Veracyte, Inc. reported a significant increase in total revenue and net income for the fiscal year ended December 31, 2025, driven by strong growth in its Decipher Prostate and Afirma tests and strategic expansion into minimal residual disease diagnostics.
NASDAQ
VCYT
Veracyte, INC
10-K: Veracyte Reports Strong 2024 Financial Results, Driven by Growth in Prostate and Thyroid Cancer Testing
Veracyte's 2024 10-K filing highlights revenue growth driven by its Decipher Prostate and Afirma tests, alongside strategic investments in minimal residual disease (MRD) testing and global expansion.
NASDAQ
VCYT
Veracyte, INC
10-K: Veracyte 10-K Filing: Details Capital Structure, Business Strategy and Regulatory Landscape
Veracyte's 10-K filing outlines its capital structure, business model, and regulatory environment, highlighting its focus on cancer diagnostics and global expansion.